AnorMED Inc. Form SC 13D/A January 26, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 3)

ANORMED, INC.

(Name of Issuer)

COMMON STOCK, NO PAR VALUE PER SHARE

(Title of Class of Securities)

035910108

(CUSIP Number)

LEO KIRBY
667 MADISON AVENUE, 19TH FLOOR
NEW YORK, NY 10021
(212) 521-2418

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

JANUARY 24, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. $|_|$

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 7 Pages

SCHEDULE 13D

CUSIP	NO. 03591010	8		PAGE		2		
1	NAMES OF REPORT	ING PERSC	ONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS					
	Julian	C. Baker	: 					
2	CHECK THE APPRO	PRIATE BC	OX IF A MEMBER OF A GROUP (See Instructions)					
3	SEC USE ONLY							
4	SOURCE OF FUNDS	(See Ins						
	WC							
5								
6	CITIZENSHIP OR PLACE OF ORGANIZATION							
	United States							
		7	SOLE VOTING POWER					
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		0					
		8	SHARED VOTING POWER					
			9,411,500					
		9	SOLE DISPOSITIVE POWER					
			0					
		10	SHARED DISPOSITIVE POWER 9,411,500					
11	AGGREGATE AMOUN	T BENEFIC	CIALLY OWNED BY EACH REPORTING PERSON					
	9,411,	500						
12	CHECK BOX IF TH		ATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES _					
13	PERCENT OF CLAS	S REPRESE	INTED BY AMOUNT IN ROW (11)					
	23.3%							
14			(See Instructions)					

SCHEDULE 13D

SIP N	NO. 03591	.0108		PAGE	3				
1	NAMES OF REF	PORTING PER	SONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS						
	Fel	ix J. Bake	r						
2	CHECK THE AF	PPROPRIATE 1	BOX IF A MEMBER OF A GROUP (See Instructions)						
3	SEC USE ONLY								
	SOURCE OF FUNDS (See Instructions)								
4	WC								
5	CHECK BOX IF	DISCLOSURI	E OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS	2(d) OR	2 (e)				
6	CITIZENSHIP	OR PLACE O	F ORGANIZATION						
	United State	es.							
	NUMBER OF	7	SOLE VOTING POWER						
Е	SHARES BENEFICIALLY		25,000						
	OWNED BY EACH	8	SHARED VOTING POWER						
	REPORTING PERSON WITH		9,411,500						
		9	SOLE DISPOSITIVE POWER 25,000						
			SHARED DISPOSITIVE POWER						
		10	9,411,500						
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON								
	9,4	136,500							
12	(See Instructions)								
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)								
	23.	3%							
	TYPE OF REPORTING PERSON (See Instructions)								
14									

This Amendment No. 3 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the "Reporting Persons") to supplement the statements on Schedule 13D previously filed by them, as heretofore amended. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

ITEM 4. PURPOSE OF TRANSACTION.

Following the filing by the Reporting Persons of their Amendment No. 2 to their statement on Schedule 13D, the Reporting Persons were informed that a special committee has been formed, consisting of all directors except for Felix Baker and Michael Abrams, to evaluate and respond to the Reporting Persons' proposal to change the composition of the board of directors of the Company.

The Reporting Persons have recommended that the following persons be elected to the board of directors of the Company.

Felix Baker, Ph.D.
Managing Partner
Baker Brothers Investments
667 Madison Ave, 17th floor
New York, NY 10021
US citizen

Joseph P. Dougherty, Ph.D. Managing Director Seaview Securities LLC 117 E. 55th St. New York, NY, 10022 US citizen

Henry J. Fuchs, MD
Executive Vice President and Chief Medical Officer
Onyx Pharmaceuticals
2100 Powell Street
Emeryville, CA 94608
US citizen

Kenneth Galbraith Gigha Consulting # 800 -15355 24th Avenue White Rock, BC V4A 2H9 Canadian citizen

Jacques Lapointe Chairman of ConjuChem, Inc. P.O. Box 398 7774 Tenth Sideroad Milton, Ontario L9T 4Y9 Canadian citizen

Page 4 of 7 Pages

Berl Nadler
Davies Ward Phillips & Vineberg LLP
44th Floor
1 First Canadian Place
Toronto, Ontario M5X 1B1
Canadian citizen

Kelvin Neu, MD Associate Baker Brothers Investments 667 Madison Ave, 17th floor New York, NY 10021 Singapore citizen

The Reporting Persons intend to continue to evaluate their alternatives as circumstances develop.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit 1 Agreement regarding the joint filing of this statement.

Page 5 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, ${\tt I}$ certify that the information set forth in this statement is true, complete and correct.

January 26, 2006

By: /s/ Julian C. Baker

Julian C. Baker

By: /s/ Felix J. Baker

Felix J. Baker

Page 6 of 7 Pages